Antitrust Risks of Co-Promotion and Co-Marketing Agreements in Pharmaceutical Patent Settlements Around the World

Download IconDownload Print IconPrint

Antitrust Risks of Co-Promotion and Co-Marketing Agreements in Pharmaceutical Patent Settlements Around the World

Speaking Engagement
In the wake of FTC v. Actavis and the European Commission's decisions against Lundbeck, J&J and Novartis, pharma patent settlement agreements remain an issue in the US and Europe. Among questions yet to be resolved is how co-promotion and co-marketing, and manufacturing arrangements that are part of patent settlement agreements should be analyzed by antitrust enforcers.

WilmerHale Partner Mark Ford will be a featured speaker on this panel.

Read More About the Event

Speakers

You May Be Interested In

AIPLA Claim Construction Webinar

April 25, 2024
Speaking Engagement

PLI's Corporate Governance – A Master Class 2024

April 25, 2024
Speaking Engagement

FIA Law & Compliance Division Conference 2024

April 24–26, 2024
Speaking Engagement
View all Events

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel